Histone deacetylase inhibitors in cancer: What have we learned?

    loading  Checking for direct PDF access through Ovid

Abstract

The authors outline the current stage in the development of histone deacetylase inhibitors in solid tumors. Despite single-agent benefit in a small number of hematologic malignancies, evidence in solid organ cancers suggests that outcomes will be more promising with combination therapy and should be the focus of future studies.

Related Topics

    loading  Loading Related Articles